Hims & Hers Health (HIMS) Acquires At-Home Lab Testing Facility
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Piper Sandler Reiterates Neutral Rating on Hims and Hers (HIMS), PT $24
February 21, 2025 12:23 PM ESTPiper Sandler analyst Korinne Wolfmeyer reiterated a Neutral rating and $24.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "We believe it's best to remain on the sidelines with HIMS following the FDA's announcement this morning that... More
Why Morgan Stanley is cautious on Hims & Hers shares
February 20, 2025 4:00 PM ESTMorgan Stanley remains cautious on Hims & Hers Health, Inc. (NYSE: HIMS) despite the companys latest move into at-home lab testing through its acquisition of Trybe Labs.
The investment bank maintains an Equal-weight rating on the stock, arguing that excitement around the companys growth potential may be outpacing realistic financial... More
Hims and Hers (HIMS) PT Raised to $21 at BofA Securities
February 20, 2025 5:18 AM ESTBofA Securities analyst Michael Cherny raised the price target on Hims and Hers (NYSE: HIMS) to $21.00 (from $18.00) while maintaining a Underperform rating.
The analyst comments "HIMS observed sales per Bloomberg Second Measure (BSM) data grew 104% y/y in January and suggests GLP-1s... More
